Symbols / PBM
PBM Chart
About
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder PTSD, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company has a strategic collaboration with PsyLabs to produce Ibogaine. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 2.84M |
| Enterprise Value | -6.31M | Income | -3.94M | Sales | — |
| Book/sh | 39.62 | Cash/sh | 23.87 | Dividend Yield | — |
| Payout | 0.00% | Employees | 12 | IPO | — |
| P/E | — | Forward P/E | — | PEG | — |
| P/S | — | P/B | 0.07 | P/C | — |
| EV/EBITDA | 1.52 | EV/Sales | — | Quick Ratio | 7.77 |
| Current Ratio | 8.09 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -389.98 | EPS next Y | — | EPS Growth | — |
| Revenue Growth | — | Earnings | — | ROA | -34.44% |
| ROE | -74.29% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 1.02M |
| Shs Float | 299.17K | Short Float | 2.28% | Short Ratio | 0.31 |
| Short Interest | — | 52W High | 468.36 | 52W Low | 2.54 |
| Beta | 0.32 | Avg Volume | 160.88K | Volume | 3.80K |
| Target Price | — | Recom | None | Prev Close | $2.76 |
| Price | $2.78 | Change | 0.72% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$2.78
Latest analyst target
3. DCF / Fair value
$-70.54
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.78
Low
—
High
—
Mean
—
News
RSS: Latest PBM news- Psyence BioMed shrinks share count from 6,388,604 to 1,022,177 - Stock Titan Wed, 28 Jan 2026 08
- Psilocybin developer’s investors back plan to combine shares up to 250-for-1 - Stock Titan ue, 17 Feb 2026 14
- Why Is PBM Stock Drawing So Much Investor Interest Today? - Stocktwits Mon, 02 Feb 2026 08
- Cigna stock nosedives on news that ending PBM rebates will lower that segment’s profit - statnews.com hu, 30 Oct 2025 07
- Psyence Biomedical Ltd. Reaches Settlement Agreement with KAOS Capital Ltd. to Resolve Shareholder Claims - Quiver Quantitative Wed, 11 Feb 2026 14
- FTC: Express Scripts settlement signals major shift in insulin pricing, PBM oversight, pharmacy transparency - Medical Economics Wed, 04 Feb 2026 21
- 12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga Fri, 13 Feb 2026 21
- Psyence, PsyLabs deal locks in psychedelic drug supply while preserving cash - Stock Titan Fri, 13 Feb 2026 23
- Psyence Biomedical Ltd. Announces Delayed Implementation of 1-for-6.25 Share Consolidation Effective February 2, 2026 - Quiver Quantitative Wed, 28 Jan 2026 08
- Psyence BioMed pays $1.5M to end KAOS Capital dispute - Stock Titan Wed, 11 Feb 2026 14
- Psyence Biomedical Ltd. Announces Postponement of Reverse Stock Split Effective Date - Quiver Quantitative ue, 20 Jan 2026 08
- Psychedelic therapy trial for patients with cancer moves forward in Australia - Stock Titan Fri, 19 Dec 2025 08
- 1-for-6.25 split leaves Psyence BioMed with 1,022,177 shares outstanding - Stock Titan Wed, 14 Jan 2026 08
- Psyence BioMed (Nasdaq: PBM) secures 50kg ibogaine supply for global clinical use - Stock Titan hu, 20 Nov 2025 08
- Psyence BioMed (Nasdaq: PBM) advances Phase IIb trial, ibogaine supply leadership - Stock Titan ue, 09 Dec 2025 08
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 78.77K | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.15 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | 500.23K | -48.62M | -3.23M | -1.85M |
| TotalUnusualItems | 525.10K | -2.49M | 26.91K | -2.29K |
| TotalUnusualItemsExcludingGoodwill | 525.10K | -2.49M | 26.91K | -2.29K |
| NetIncomeFromContinuingOperationNetMinorityInterest | 1.01M | -51.16M | -3.21M | -1.86M |
| ReconciledDepreciation | 4.27K | 240.00 | 0.00 | |
| EBITDA | 1.03M | -51.11M | -3.21M | -1.86M |
| EBIT | 1.02M | -51.11M | -3.21M | -1.86M |
| NetInterestIncome | 86.52K | -50.81K | 1.55K | 0.00 |
| InterestExpense | 9.27K | 52.94K | 0.00 | |
| InterestIncome | 95.79K | 2.13K | 1.55K | 0.00 |
| NormalizedIncome | 565.45K | -48.67M | -3.23M | -1.86M |
| NetIncomeFromContinuingAndDiscontinuedOperation | 1.01M | -51.16M | -3.21M | -1.86M |
| TotalExpenses | 3.66M | 44.23M | 3.23M | 1.86M |
| DilutedAverageShares | 3.88K | 3.58K | 3.41K | 3.41K |
| BasicAverageShares | 3.88K | 3.58K | 3.41K | 3.41K |
| DilutedEPS | 261.02 | -14.27K | -940.02 | -544.78 |
| BasicEPS | 261.02 | -14.27K | -940.02 | -544.78 |
| DilutedNIAvailtoComStockholders | 1.01M | -51.16M | -3.21M | -1.86M |
| NetIncomeCommonStockholders | 1.01M | -51.16M | -3.21M | -1.86M |
| NetIncome | 1.01M | -51.16M | -3.21M | -1.86M |
| NetIncomeIncludingNoncontrollingInterests | 1.01M | -51.16M | -3.21M | -1.86M |
| NetIncomeContinuousOperations | 1.01M | -51.16M | -3.21M | -1.86M |
| PretaxIncome | 1.01M | -51.16M | -3.21M | -1.86M |
| OtherIncomeExpense | 4.59M | -6.87M | 26.91K | -2.29K |
| OtherNonOperatingIncomeExpenses | 4.06M | -4.39M | ||
| SpecialIncomeCharges | 0.00 | -2.18M | 0.00 | |
| OtherSpecialCharges | -281.50K | |||
| RestructuringAndMergernAcquisition | 0.00 | 2.46M | 0.00 | |
| GainOnSaleOfSecurity | 525.10K | -308.94K | 26.91K | -2.29K |
| NetNonOperatingInterestIncomeExpense | 86.52K | -50.81K | 1.55K | 0.00 |
| InterestExpenseNonOperating | 9.27K | 52.94K | 0.00 | |
| InterestIncomeNonOperating | 95.79K | 2.13K | 1.55K | 0.00 |
| OperatingIncome | -3.66M | -44.23M | -3.23M | -1.86M |
| OperatingExpense | 3.66M | 44.23M | 3.23M | 1.86M |
| OtherOperatingExpenses | 41.48M | |||
| DepreciationAmortizationDepletionIncomeStatement | 4.27K | 240.00 | 0.00 | |
| DepreciationAndAmortizationInIncomeStatement | 4.27K | 240.00 | 0.00 | |
| DepreciationIncomeStatement | 4.27K | 240.00 | 0.00 | |
| ResearchAndDevelopment | 342.17K | 954.59K | 1.61M | 137.24K |
| SellingGeneralAndAdministration | 3.32M | 1.80M | 1.63M | 1.72M |
| SellingAndMarketingExpense | 483.53K | 80.60K | 7.03K | 17.51K |
| GeneralAndAdministrativeExpense | 2.83M | 1.72M | 1.62M | 1.70M |
| OtherGandA | 2.83M | 1.72M | 1.62M | 1.70M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 90.88K | 3.58K | 3.41K | 3.41K |
| ShareIssued | 90.88K | 3.58K | 3.41K | 3.41K |
| NetDebt | 9.71M | |||
| TotalDebt | 10.45M | |||
| TangibleBookValue | 6.72M | -10.97M | -200.44K | 1.70M |
| InvestedCapital | 6.72M | -524.65K | -200.44K | 1.70M |
| WorkingCapital | 5.97M | -10.98M | -200.44K | 1.70M |
| NetTangibleAssets | 6.72M | -10.97M | -200.44K | 1.70M |
| CommonStockEquity | 6.72M | -10.97M | -200.44K | 1.70M |
| TotalCapitalization | 6.72M | -10.97M | -200.44K | 1.70M |
| TotalEquityGrossMinorityInterest | 6.72M | -10.97M | -200.44K | 1.70M |
| StockholdersEquity | 6.72M | -10.97M | -200.44K | 1.70M |
| OtherEquityInterest | 1.07M | -200.56K | 1.70M | 4.80M |
| GainsLossesNotAffectingRetainedEarnings | 351.20K | 361.06K | 165.36K | |
| RetainedEarnings | -56.45M | -57.46M | -6.30M | |
| CapitalStock | 61.75M | 46.13M | 5.93M | |
| CommonStock | 61.75M | 46.13M | 5.93M | |
| TotalLiabilitiesNetMinorityInterest | 594.37K | 12.10M | 1.79M | 131.76K |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentLiabilities | 594.37K | 12.10M | 1.79M | 131.76K |
| OtherCurrentLiabilities | 200.10K | 901.61K | ||
| CurrentDebtAndCapitalLeaseObligation | 10.45M | |||
| CurrentDebt | 10.45M | |||
| OtherCurrentBorrowings | 10.45M | |||
| CurrentProvisions | 81.85K | 66.90K | ||
| PayablesAndAccruedExpenses | 312.42K | 688.30K | 1.79M | 131.76K |
| CurrentAccruedExpenses | 50.48K | 125.95K | 162.56K | 94.87K |
| Payables | 261.94K | 562.35K | 1.63M | 36.89K |
| AccountsPayable | 261.94K | 562.35K | 1.63M | 36.89K |
| TotalAssets | 7.32M | 1.13M | 1.59M | 1.83M |
| TotalNonCurrentAssets | 756.10K | 5.49K | 0.00 | 0.00 |
| InvestmentsAndAdvances | 745.00K | 0.00 | ||
| InvestmentinFinancialAssets | 745.00K | 0.00 | ||
| FinancialAssetsDesignatedasFairValueThroughProfitorLossTotal | 745.00K | 0.00 | ||
| NetPPE | 11.10K | 5.49K | 0.00 | |
| AccumulatedDepreciation | -4.51K | -240.00 | 0.00 | |
| GrossPPE | 15.60K | 5.73K | 0.00 | |
| OtherProperties | 5.73K | |||
| MachineryFurnitureEquipment | 15.60K | 5.73K | ||
| CurrentAssets | 6.56M | 1.13M | 1.59M | 1.83M |
| RestrictedCash | 35.96K | 29.61K | 29.56K | 36.23K |
| PrepaidAssets | 251.80K | 322.13K | 77.05K | 5.39K |
| Receivables | 137.35K | 41.75K | 149.37K | 39.55K |
| OtherReceivables | 137.35K | 41.75K | 149.37K | 39.55K |
| CashCashEquivalentsAndShortTermInvestments | 6.14M | 733.19K | 1.33M | 1.75M |
| CashAndCashEquivalents | 6.14M | 733.19K | 1.33M | 1.75M |
| CashFinancial | 6.14M | 733.19K | 1.33M | 1.75M |
| Line Item | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| FreeCashFlow | -3.74M | -2.95M | -1.59M | -1.40M |
| RepaymentOfDebt | 0.00 | -150.00K | 0.00 | |
| IssuanceOfDebt | 7.41M | 2.50M | 0.00 | |
| IssuanceOfCapitalStock | 1.74M | 0.00 | 0.00 | |
| CapitalExpenditure | -9.88K | -5.73K | ||
| EndCashPosition | 6.14M | 733.19K | 1.33M | 1.76M |
| BeginningCashPosition | 733.19K | 1.33M | 1.75M | 4.81M |
| ChangesInCash | 5.40M | -601.09K | -419.16K | -3.06M |
| FinancingCashFlow | 9.15M | 2.35M | 1.17M | -1.63M |
| CashFlowFromContinuingFinancingActivities | 9.15M | 2.35M | 1.17M | -1.63M |
| NetOtherFinancingCharges | 1.17M | -1.63M | ||
| NetCommonStockIssuance | 1.74M | 0.00 | 0.00 | |
| CommonStockIssuance | 1.74M | 0.00 | 0.00 | |
| NetIssuancePaymentsOfDebt | 7.41M | 2.35M | 0.00 | |
| NetShortTermDebtIssuance | 1.00M | 2.35M | 0.00 | |
| ShortTermDebtPayments | 0.00 | -150.00K | 0.00 | |
| ShortTermDebtIssuance | 1.00M | 2.50M | 0.00 | |
| NetLongTermDebtIssuance | 6.41M | 0.00 | 0.00 | |
| LongTermDebtIssuance | 6.41M | 0.00 | 0.00 | |
| InvestingCashFlow | -16.23K | -5.73K | 0.00 | -32.04K |
| CashFlowFromContinuingInvestingActivities | -16.23K | -5.73K | 0.00 | -32.04K |
| NetOtherInvestingChanges | -6.35K | -32.04K | ||
| NetPPEPurchaseAndSale | -9.88K | -5.73K | 0.00 | |
| PurchaseOfPPE | -9.88K | -5.73K | 0.00 | |
| OperatingCashFlow | -3.73M | -2.95M | -1.59M | -1.40M |
| CashFlowFromContinuingOperatingActivities | -3.73M | -2.95M | -1.59M | -1.40M |
| ChangeInWorkingCapital | -386.20K | -1.17M | 1.48M | 129.74K |
| ChangeInPayablesAndAccruedExpense | -360.93K | -1.04M | 1.66M | 29.56K |
| ChangeInPrepaidAssets | 70.33K | -245.07K | -71.67K | 128.16 |
| ChangeInReceivables | -95.60K | 107.62K | -109.86K | 100.05K |
| OtherNonCashItems | 218.41K | 43.58M | ||
| StockBasedCompensation | 0.00 | 317.88K | 221.29K | 332.07K |
| UnrealizedGainLossOnInvestmentSecurities | -4.06M | 5.46M | 0.00 | |
| DepreciationAmortizationDepletion | 4.27K | 240.00 | 0.00 | |
| DepreciationAndAmortization | 4.27K | 240.00 | 0.00 | |
| Depreciation | 4.27K | 240.00 | 0.00 | |
| OperatingGainsLosses | -519.31K | 28.41K | -84.50K | |
| GainLossOnInvestmentSecurities | -509.45K | 306.25K | ||
| NetForeignCurrencyExchangeGainLoss | -9.86K | 3.66K | -84.50K | |
| GainLossOnSaleOfBusiness | -22.97K | 0.00 | 0.00 | |
| NetIncomeFromContinuingOperations | 1.01M | -51.16M | -3.21M | -1.86M |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for PBM
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|